EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics

Brendan T Finicle iD, Kazumi H Eckenstein, Alexey S Revenko, Brooke A Anderson, W Brad Wan, Alison N McCracken, Daniel Gil, David A Fruman, Stephen Hanessian, Punit P Seth iD, Aimee L Edinger iD

Nucleic Acids Research · 2023

DOI: 10.1093/nar/gkad023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Brendan T Finicle und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental and Cell Biology, University of California Irvine, Irvine, CA, USA. Hauptthemen laut MEDLINE: Oligonucleotides, Endosomes. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Ono Pharma Foundation Breakthrough Science Initiative, Ionis Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inefficient endosomal escape remains the primary barrier to the broad application of oligonucleotide therapeutics. Liver uptake after systemic administration is sufficiently robust that a therapeutic effect can be achieved but targeting extrahepatic tissues remains challenging. Prior attempts to improve oligonucleotide activity using small molecules that increase the leakiness of endosomes have failed due to unacceptable toxicity. Here, we show that the well-tolerated and orally bioavailable synthetic sphingolipid analog, SH-BC-893, increases the activity of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) up to 200-fold in vitro without permeabilizing endosomes. SH-BC-893 treatment trapped endocytosed oligonucleotides within extra-lysosomal compartments thought to be more permeable due to frequent membrane fission and fusion events. Simultaneous disruption of ARF6-dependent endocytic recycling and PIKfyve-dependent lysosomal fusion was necessary and sufficient for SH-BC-893 to increase non-lysosomal oligonucleotide levels and enhance their activity. In mice, oral administration of SH-BC-893 increased ASO potency in the liver by 15-fold without toxicity. More importantly, SH-BC-893 enabled target RNA knockdown in the CNS and lungs of mice treated subcutaneously with cholesterol-functionalized duplexed oligonucleotides or unmodified ASOs, respectively. Together, these results establish the feasibility of using a small molecule that disrupts endolysosomal trafficking to improve the activity of oligonucleotides in extrahepatic tissues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligonucleotidesEndosomesAnimalsMiceEndocytosisBiological TransportOligonucleotides, AntisenseRNA, Small Interfering

Substanzen

OligonucleotidesOligonucleotides, AntisenseRNA, Small Interfering

Autor:innen und Institutionen

  • Department of Developmental and Cell Biology, University of California Irvine, Irvine, CA, USA.
  • Ionis Pharmaceuticals, Carlsbad, CA, USA.
  • Siege Pharmaceuticals, Irvine, CA, USA.
  • Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA, USA.
  • Department of Chemistry, Université de Montréal, Montréal, QC, Canada.
  • Department of Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA.

ORCID-Profile: Brendan T Finicle, Punit P Seth, Aimee L Edinger

Förderung

  • NCI NIH HHS
  • Ono Pharma Foundation Breakthrough Science Initiative
  • Ionis Pharmaceuticals
  • NIH
  • NCI
  • Chao Family Comprehensive Cancer Center Optical Biology Center
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Finicle, B. T., Eckenstein, K. H., Revenko, A. S., Anderson, B. A., Wan, W. B., McCracken, A. N., Gil, D., Fruman, D. A., Hanessian, S., Seth, P. P., & Edinger, A. L. (2023). Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad023

Vancouver

Finicle BT, Eckenstein KH, Revenko AS, Anderson BA, Wan WB, McCracken AN, et al. Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics. Nucleic Acids Research. 2023. doi:10.1093/nar/gkad023

BibTeX
@article{Finicle2023,
  author = {Finicle, Brendan T and Eckenstein, Kazumi H and Revenko, Alexey S and Anderson, Brooke A and Wan, W Brad and McCracken, Alison N and Gil, Daniel and Fruman, David A and Hanessian, Stephen and Seth, Punit P and Edinger, Aimee L},
  title = {Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics},
  journal = {Nucleic Acids Research},
  year = {2023},
  doi = {10.1093/nar/gkad023}
}
Kostenlos starten →